Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 166, Issue 2, Pages 532-553
Publisher
Wiley
Online
2012-01-31
DOI
10.1111/j.1476-5381.2012.01873.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets
- (2011) Federica Barbieri et al. BIOCHEMICAL PHARMACOLOGY
- Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
- (2011) E Giovannetti et al. BRITISH JOURNAL OF CANCER
- Advances in the biology of malignant pleural mesothelioma
- (2011) P.A. Zucali et al. CANCER TREATMENT REVIEWS
- Pleural mesothelioma side populations have a precursor phenotype
- (2011) Claudia Frei et al. CARCINOGENESIS
- Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy
- (2011) Mir Alireza Hoda et al. Journal of Thoracic Oncology
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
- (2011) Tom Treasure et al. LANCET ONCOLOGY
- Germline BAP1 mutations predispose to malignant mesothelioma
- (2011) Joseph R Testa et al. NATURE GENETICS
- The cancer stem cell: premises, promises and challenges
- (2011) Hans Clevers NATURE MEDICINE
- Onconase mediated NFKβ downregulation in malignant pleural mesothelioma
- (2011) C M Goparaju et al. ONCOGENE
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
- (2011) David A. Proia et al. PLoS One
- Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma
- (2011) Roberto E. Favoni et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- New directions in the management of advanced pancreatic cancer: a review
- (2010) Caio M. Rocha-Lima ANTI-CANCER DRUGS
- Identification of cancer stem cell markers in human malignant mesothelioma cells
- (2010) Farhana Ishrat Ghani et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent
- (2010) Deborah A Altomare et al. BMC CANCER
- In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells
- (2010) Alice Melotti et al. BMC CANCER
- The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
- (2010) J E Nutt et al. BRITISH JOURNAL OF CANCER
- Sorafenib inhibits ERK1/2 and MCL-1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma
- (2010) Sharyn I. Katz et al. CANCER BIOLOGY & THERAPY
- In vitro anti-mesothelioma activity of cisplatin–gemcitabine combinations: evidence for sequence-dependent effects
- (2010) Ilaria Zanellato et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Origins and Implications of Intratumor Heterogeneity
- (2010) F. Michor et al. Cancer Prevention Research
- In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth
- (2010) Naohiko Hamaguchi et al. CANCER SCIENCE
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
- (2010) R. E. Favoni et al. CURRENT CANCER DRUG TARGETS
- Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma
- (2010) Federica Perrone et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib: a clinical and pharmacologic review
- (2010) Renuka Iyer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma
- (2010) Yoshinori Suzuki et al. INTERNATIONAL JOURNAL OF CANCER
- The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies
- (2010) Petros Nikolinakos et al. Journal of Thoracic Oncology
- Characterization of side population cells in human malignant mesothelioma cell lines
- (2010) Kiyonori Kai et al. LUNG CANCER
- Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
- (2010) Daniela Stoppoloni et al. Molecular Cancer
- Spatial control of EGF receptor activation by reversible dimerization on living cells
- (2010) Inhee Chung et al. NATURE
- Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
- (2010) Tong T. Zhao et al. PLoS One
- Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
- (2010) Haining Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K inhibitors for cancer treatment: where do we stand?
- (2009) Sauveur-Michel Maira et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines
- (2009) Kiyonori Kai et al. CANCER LETTERS
- Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
- (2009) Koji Kawaguchi et al. CARCINOGENESIS
- E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
- (2009) K. Ikuta et al. CLINICAL CANCER RESEARCH
- Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
- (2009) F. Vandermeers et al. CLINICAL CANCER RESEARCH
- Molecular Targets in Malignant Pleural Mesothelioma Treatment
- (2009) Giulia Pasello et al. CURRENT DRUG TARGETS
- Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines
- (2009) Joyce E. Nutt et al. EUROPEAN JOURNAL OF CANCER
- Malignant pleural mesothelioma: current treatments and emerging drugs
- (2009) Carmen Belli et al. EXPERT OPINION ON EMERGING DRUGS
- Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors
- (2009) Fabrizio Griffero et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma
- (2009) Mor-Li Hartman et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines
- (2009) Sara L. O’Kane et al. LUNG CANCER
- Farnesyltransferase Inhibitor as Anticancer Agent
- (2009) Anuj Agrawal et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR Mediates Survival Signals in Malignant Mesothelioma Grown as Tumor Fragment Spheroids
- (2008) Shannon M. Wilson et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
- (2008) Paolo A. Zucali et al. CANCER
- Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement
- (2008) Hirokazu Ogino et al. CANCER LETTERS
- Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines
- (2008) Shinjiro Nagai et al. CHEMOTHERAPY
- Newer Cytotoxic Agents: Attacking Cancer Broadly
- (2008) B. A. Teicher CLINICAL CANCER RESEARCH
- Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
- (2008) P. Bertino et al. CLINICAL CANCER RESEARCH
- Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
- (2008) H. Choy et al. CLINICAL CANCER RESEARCH
- Systemic Treatments for Mesothelioma: Standard and Novel
- (2008) Hedy Lee Kindler CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Ranpirnase (Onconase®), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy
- (2008) Intae Lee EXPERT OPINION ON BIOLOGICAL THERAPY
- Targeting STAT3 in cancer: how successful are we?
- (2008) Peibin Yue et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids
- (2008) Dario Barbone et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma
- (2008) Junichi Okamoto et al. Journal of Thoracic Oncology
- MET as a target for treatment of chest tumors
- (2008) Nicole A. Cipriani et al. LUNG CANCER
- COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro
- (2008) Huan-Ching Chuang et al. Molecular Cancer
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now